Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

10x Genomics, Inc. - Common Stock (NQ:TXG)

8.770 -0.390 (-4.26%)
Streaming Delayed Price Updated: 1:49 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 10x Genomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
2 Reasons to Sell TXG and 1 Stock to Buy Instead
What a brutal six months it’s been for 10x Genomics. The stock has dropped 52.1% and now trades at $10.59, rattling many shareholders. This was partly due to its softer quarterly results and might have... 
Via StockStory
1 Stock Under $50 on Our Watchlist and 2 to Ignore
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns. 
Via Benzinga
Why 10x Genomics (TXG) Shares Are Falling Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full-year... 
Via StockStory
Earnings Scheduled For February 12, 2025
Via Benzinga
The Analyst Verdict: 10x Genomics In The Eyes Of 6 Experts
Via Benzinga
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results
Via Benzinga
MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s... 
Via StockStory
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 
Via StockStory
Cathie Wood's Ark Invest Bets Big On Amazon, Roblox And Illumina While Trimming Palantir Stake After Alex Karp-Led Company Touched An All-Time High On Thursday
Ark Invest made significant trades on Friday, including buying Amazon and Roblox stock and selling Palantir stock. Other key trades were also made. 
Via Benzinga
Looking Into 10x Genomics's Recent Short Interest
Via Benzinga
Where 10x Genomics Stands With Analysts
Via Benzinga
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV. 
Via Benzinga
Cathie Wood's Ark Invest Dumps Over $10 Million Worth Of Palantir Stock As AI Competition Heats Up
On Thursday, Jan. 30, 2025 Cathie Wood-led Ark Invest sold $10.4 million worth of Palantir shares through its flagship fund. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The aggressive growth fund investor has slowed her shopper this holiday season, but she still made time to build up some of her existing positions. 
Via The Motley Fool
Ray Dalio's Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?
Ray Dalio's Bridgewaterand Ark Invest trimmed their Microsoft positions, signaling a shift in Big Tech's role in portfolios. 
Via Benzinga
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
S&P Moves Lower; Domino's Pizza Posts Mixed Q3 Results
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Surges 3%; Delta Air Lines Posts Downbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Dow Falls Over 100 Points; US Inflation Rate Slows To 2.4% In September
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
10x Genomics Crashes After 'Disruptive' Reorg Upsets Third-Quarter Sales
The company is undergoing a reorganization that has proven more "disruptive" than previously expected. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead
10x Genomics reported Q3 2024 revenue of $151.7 million, down 1% from last year. Instruments revenue dropped 46%, while consumables grew 10%. CEO Serge Saxonov acknowledged the challenges faced but... 
Via Benzinga
Nasdaq, S&P 500 Futures Slip As September CPI Data Looms, Tesla On Radar Ahead Of Robotaxi Event: Strategist Offers Stock Tips Aligned With Presidential Candidates' Trade Policies
The imminent release of the September consumer price inflation report is keeping sentiment guarded as the index futures trade modestly lower early Thursday. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why BloomZ Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Delta Air Lines, Domino's Pizza And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.